Suppr超能文献

NOTCH1 突变是慢性淋巴细胞白血病患者生存的独立预测因子。

Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.

机构信息

Division of Hematology, Department of Clinical and Experimental Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy.

出版信息

Blood. 2012 Jan 12;119(2):521-9. doi: 10.1182/blood-2011-09-379966. Epub 2011 Nov 10.

Abstract

Analysis of the chronic lymphocytic leukemia (CLL) coding genome has recently disclosed that the NOTCH1 proto-oncogene is recurrently mutated at CLL presentation. Here, we assessed the prognostic role of NOTCH1 mutations in CLL. Two series of newly diagnosed CLL were used as training (n = 309) and validation (n = 230) cohorts. NOTCH1 mutations occurred in 11.0% and 11.3% CLL of the training and validation series, respectively. In the training series, NOTCH1 mutations led to a 3.77-fold increase in the hazard of death and to shorter overall survival (OS; P < .001). Multivariate analysis selected NOTCH1 mutations as an independent predictor of OS after controlling for confounding clinical and biologic variables. The independent prognostic value of NOTCH1 mutations was externally confirmed in the validation series. The poor prognosis conferred by NOTCH1 mutations was attributable, at least in part, to shorter treatment-free survival and higher risk of Richter transformation. Although NOTCH1 mutated patients were devoid of TP53 disruption in more than 90% cases in both training and validation series, the OS predicted by NOTCH1 mutations was similar to that of TP53 mutated/deleted CLL. NOTCH1 mutations are an independent predictor of CLL OS, tend to be mutually exclusive with TP53 abnormalities, and identify cases with a dismal prognosis.

摘要

对慢性淋巴细胞白血病 (CLL) 编码基因组的分析最近揭示,NOTCH1 原癌基因在 CLL 发病时经常发生突变。在这里,我们评估了 NOTCH1 突变在 CLL 中的预后作用。两个新诊断的 CLL 系列被用作训练 (n = 309) 和验证 (n = 230) 队列。NOTCH1 突变分别发生在训练系列和验证系列中的 11.0%和 11.3%的 CLL 中。在训练系列中,NOTCH1 突变使死亡风险增加了 3.77 倍,并导致总生存期 (OS) 缩短 (P <.001)。多变量分析在控制混杂的临床和生物学变量后,选择 NOTCH1 突变作为 OS 的独立预测因子。NOTCH1 突变的独立预后价值在验证系列中得到了外部证实。NOTCH1 突变导致的不良预后至少部分归因于无治疗缓解期较短和 Richter 转化风险较高。尽管在训练和验证系列中,NOTCH1 突变患者的 TP53 缺失超过 90%,但 NOTCH1 突变预测的 OS 与 TP53 突变/缺失的 CLL 相似。NOTCH1 突变是 CLL OS 的独立预测因子,倾向于与 TP53 异常相互排斥,并确定预后不良的病例。

相似文献

4
NOTCH1 mutations in CLL associated with trisomy 12.慢性淋巴细胞白血病中与 12 三体相关的 NOTCH1 突变。
Blood. 2012 Jan 12;119(2):329-31. doi: 10.1182/blood-2011-10-386144. Epub 2011 Nov 15.

引用本文的文献

本文引用的文献

5
Understanding and managing ultra high-risk chronic lymphocytic leukemia.理解和管理超高危慢性淋巴细胞白血病。
Hematology Am Soc Hematol Educ Program. 2010;2010:481-8. doi: 10.1182/asheducation-2010.1.481.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验